Inotek Pharmaceuticals competitors

Laurent Fischer joined Tobira's Board of Directors in April 2009 and became Chief Executive Officer in 2014. Laurent Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time he was Chairman and Chief Executive Officer of Jennerex Inc., a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics (NASDAQ: OCRX), where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa®, the first treatment approved for irritable bowel syndrome in Europe. Laurent Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Laurent Fischer was responsible for the global launch of Sustiva® the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla® and was involved in the launch of Invirase®, the first protease inhibitor, in the United States. Laurent Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

John Ratliff served as Chief Executive Officer of Covance Drug Development, the world’s most comprehensive drug development company. He is a highly respected biopharmaceutical leader, with extensive experience in increasingly influential roles in the industry. In 2018, Ratliff was appointed Chairman for the Association of Clinical Research Organizations. Previously John was president and CEO of HUYA Bioscience International. His healthcare industry experience also includes almost 10 years at Quintiles, the world’s largest provider of product development and integrated healthcare services, where he served as Chief Financial Officer before becoming President and Chief Operating Officer. He was a member of the Quintiles board of directors. Prior roles throughout his career included CFO at Acterna, a provider of communications test solutions for telecommunications and cable network operators, and positions of increasing responsibility during his 19-year tenure at IBM.

David Seltzer is a Chairman/Pres/CEO/Treasurer at HI TECH PHARMACAL CO INC, Board Member at NovelStem International Corp, and Owner at Leading Pharma. He has experience at Bergen Brunswig Corp and AMERISOURCEBERGEN CORP and has worked as Exec VP:Admin/Treasurer/Secy at HI TECH PHARMACAL CO INC, Treasurer/Secretary at HI TECH PHARMACAL CO INC, and VP:Admin/COO/Treasurer/Secy at HI TECH PHARMACAL CO INC. David attended Queens University of Charlotte.

Ian Lennox is a CEO/Chairman at Olon Ricerca Bioscience LLC. He attended HBSc and MBA.

Dr. Rienhoff is a physician, entrepreneur and founder of several biotech and presently serves as CEO of Imago BioSciences. Dr. Rienhoff was the founder and CEO of FerroKin Biosciences, a development stage company that was acquired by Shire in for $325 million in 2012. He has more than 20 years experience as both a venture investor and entrepreneur in the life science sector. He was a partner at New Enterprise Associates and later, a director of Abingworth Management Ltd., running their US operation. Dr. Rienhoff is an Adjunct Scientist at the Children's Hospital Oakland Research Institute. He received his M.D. from the Johns Hopkins University School of Medicine and his B.A. from Williams College.

Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to several successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace. After earning his doctorate in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-Aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization. Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.